A cost-effectiveness analysis of three treatments for age-related macular degeneration
This study evaluated the cost-effectiveness of pegaptanib sodium or ranibizumab injections, compared with photodynamic therapy (PDT) with verteporfin for treating choroidal neovascularisation in patients with age-related macular degeneration. The authors concluded that pegaptanib was inferior to PDT in costs and effectiveness and ranibizumab was unlikely to be cost-effective, at the accepted threshold of 50,000 US dollars per quality-adjusted life-year. The methods could not be assessed and there was no full incremental analysis. The authors' conclusions should be interpreted with caution.